MeiraGTx Holdings plc (NASDAQ: MGTX) is a Healthcare company (Biotechnology) with a market capitalization of $827M. The Maz Rating grades it against the other companies in its sector.
MeiraGTx Holdings plc's current Maz Rating and its five factor grades are for members: log in to see them.
At $8.46, MeiraGTx Holdings plc trades at 9.9x trailing earnings, 2.1x sales and 3.8x book value, with an EV/EBITDA of 3.0. Over the last twelve months it generated about $402M of revenue and $83M of net income. It runs a gross margin of 95.7%, an operating margin of 44.8% and a net margin of 19.5%. It shows return on equity of 85.4%, return on invested capital of 48.0% and a free cash flow yield of -1.1%. On the balance sheet: a debt-to-equity ratio of 0.62 and a current ratio of 4.62. Over the past 52 weeks the share price ranged from $6.62 to $15.35, with a beta of 1.35.
MeiraGTx Holdings plc does not currently pay a dividend.
7 Wall Street analyst ratings cover the stock: 7 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, MeiraGTx Holdings plc (MGTX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 11.6% / 30% · (Cash+Inv) / Mkt Cap (36m) 21.1% / 30% · Interest income / Revenue 23.9% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 11.6% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 17.6% / 33% · Receivables / Mkt Cap (36m) 2.82% / 49% · Interest income / Revenue 23.9% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 11.6% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 17.6% / 33.33% · Receivables / Mkt Cap (24m) 2.82% / 33.33% · Interest income / Revenue 23.9% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 28.8% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 35.9% / 33.33% · Receivables / Avg Assets (4Q) 8.48% / 33.33% · Interest income / Revenue 23.9% / 5% | Fail |
| FTSE | Debt / Total Assets 29.6% / 33.33% · (Cash+ST Inv) / Total Assets 44.9% / 33.33% · (Cash+Recv) / Total Assets 52.0% / 33.33% · Interest income / Revenue 23.9% / 5% | Fail |
No. As of September 2026, MeiraGTx Holdings plc (MGTX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. MeiraGTx Holdings plc is over the AAOIFI limit on Interest income / Revenue.
About 23.9% of each dividend: MeiraGTx Holdings plc's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.